Marc-Olivier Turgeon PhD

Marc is the Vice President of Business Development & Strategy at T-Therapeutics. He brings extensive biotech experience and a complementary skillset to the team with his background as a venture capital investor.

Prior to joining T-Therapeutics, Marc was part of the Forbion investment team where he played a key role in investments across the portfolio. He served as Board Director on the board of Progentos Therapeutics, as well as held board observer positions with Pheon Therapeutics and Tessellate Bio (€500M licensing deal with Boehringer Ingelheim). He was also closely involved with investments in Navigator Medicines, Engrail Therapeutics, and Crescent Biopharma ($CBIO).

Marc holds a PhD in Oncology from the Institute of Cancer Research in London, and a MSc and BSc from McGill University.